1 |
Arkema EV, Svenungsson E, von Euler M, et al. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study[J]. Ann Rheum Dis, 2017, 76(9): 1544-1549.
|
2 |
Aviña-Zubieta JA, Vostretsova K, De Vera MA, et al. The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: a general population-based study[J]. Semin Arthritis Rheum, 2015, 45(2): 195-201.
|
3 |
Guraieb-Chahín P, Cantú-Brito C, Soto-Mota A, et al. Stroke in systemic lupus erythematosus: epidemiology, mechanism, and long-term outcome[J]. Lupus, 2020, 29(5): 437-445.
|
4 |
Sciascia S, Sanna G, Murru V, et al. GAPSS: the global anti-phospholipid syndrome score[J]. Rheumatology (Oxford), 2013, 52(8): 1397-1403.
|
5 |
Sciascia S, Radin M, Sanna G, et al. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis[J]. Rheumatology (Oxford), 2018, 57(4): 661-665.
|
6 |
Radin M, Sciascia S, Erkan D, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort[J]. Semin Arthritis Rheum, 2019, 49(3): 464-468.
|
7 |
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64(8): 2677-2686.
|
8 |
D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study[J]. Circulation, 2008, 117(6): 743-753.
|
9 |
Garcia L, Velloso MS, Martire MV, et al. Validation of the adjusted global antiphospholipid syndrome score in systemic lupus erythematosus patients in Argentina[J]. Lupus, 2020, 29(14): 1866-1872.
|
10 |
Radin M, Schreiber K, Costanzo P, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction[J]. Int J Cardiol, 2017, 240: 72-77.
|
11 |
Bahl V, Hu HM, Henke PK, et al. A validation study of a retrospective venous thromboembolism risk scoring method[J]. Ann Surg, 2010, 251(2): 344-350.
|
12 |
Hernández-Molina G, Espericueta-Arriola G, Cabral AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome[J]. Clin Exp Rheumatol, 2013, 31(3): 382-388.
|
13 |
Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events[J]. Arthritis Rheum, 2012, 64(2): 504-512.
|
14 |
Chen J, Sun S, Yan Q, et al. Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study[J]. Clin Rheumatol, 2016, 35(2): 333-340.
|
15 |
Zuily S, de Laat B, Mohamed S, et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study[J]. Rheumatology (Oxford), 2015, 54(11): 2071-2075.
|
16 |
Sciascia S, Cuadrado MJ, Sanna G, et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort[J]. Arthritis Care Res (Hoboken), 2014, 66(12): 1915-1920.
|